EuBiologics to start phase two clinical study of its COVID-19 vaccine candidate

EuBiologics announced Wednesday that it will commence a Phase II trial of its COVID-19 vaccine candidate EuCOVAC-19, reported The Korea Herald.

The company said it plans to conduct the study of its synthetic antigen-based vaccine candidate from the end of this month on a total of 230 people, with an aim of completing it by October.

EuBiologics said it has seen positive results from the Phase I trial in terms of the safety and immunogenicity of the vaccine candidate.

The firm had administered the vaccine candidate on 50 adults between ages 19 to 50 after receiving approval in January from the Korean Ministry of Food and Drug Safety for its Phase I and II study plans.

Meanwhile, EuBiologics is also conducting nonclinical laboratory study of an experimental vaccine that could work on COVID-19 variants, according to the company.